Table 1. Epidemiologic, clinical and laboratory characteristics of patients with cirrhosis.
| Patients with stable cirrhosis n = 99 |
Patients with acute decompensation n = 54 |
p -Value | ||
|---|---|---|---|---|
| Gender (male/female) | 47/52 | 31/23 | n.a. | |
| Age (y) a | 57 (24–75) | 57 (33–80) | 0.698 | |
| Aetiology, n (%) | Alcohol | 63 (63.6) | 43 (79.6) | 0.099 |
| Viral | 27 (27.3) | 7 (13.0) | ||
| Other | 9 (9.1) | 4 (7.4) | ||
| Child-Pugh stage, n (%) | A B |
51 (51.5) 43 (43.4) |
6 (11.1) 24 (44.4) |
< 0.001 |
| C | 5 (5.1) | 24 (44.4) | ||
| MELD score | 12 (9–14) | 16 (12–23) | < 0.001 | |
| White blood cell count (g/L) a | 5.3 (4.2–6.8) | 7.1 (4.6–11.0) | 0.003 | |
| Platelet count (g/L) a | 112 (70–161) | 108 (71–165) | 0.924 | |
| Serum sodium (mmol/L) a | 141 (138–143) | 138 (134–141) | 0.001 | |
| Serum creatinine (μmol/L) a | 64 (54–84) | 75 (50–133) | 0.122 | |
| C-reactive protein (mg/L) a | 3.8 (1.5–9.0) | 18.1 (6.0–48.5) | < 0.001 | |
| Serum bilirubin (μmol/L) a | 31 (19–50) | 61 (31–179) | < 0.001 | |
| Aspartate aminotransferase (U/L) a | 51 (33–83) | 67 (45–125) | 0.002 | |
| Alanine aminotransferase (U/L) a | 33 (21–57) | 31 (21–58) | 0.887 | |
| Serum albumin (g/L) a | 37 (33–41) | 28.5 (24–32) | < 0.001 | |
| INR a | 1.1 (1.2–1.3) | 1.4 (1.2–1.7) | < 0.001 | |
| Ascites present, n (%) | 41 (41.4) | 38 (70.0) | 0.001 | |
| Patients with acute decompensation, n (%) |
Tense ascites formation | 25 (46.3) | n.a. | |
| Upper GI bleeding | 17 (31.5) | n.a. | ||
| HE | 11 (20.4) | n.a. | ||
| Bacterial infection | 30 (55.6) | n.a. | ||
| Six-month mortality, n (%) | 4 (4.0) | 17 (31.5) | < 0.001 | |
Abbreviations: GI, gastrointestinal; HE, hepatic encephalopathy; INR, international normalized ratio; MELD, model for end-stage liver disease; n.a., not applicable.
a
Median, interquartile range.